TWI561525B - - Google Patents
Info
- Publication number
- TWI561525B TWI561525B TW101144467A TW101144467A TWI561525B TW I561525 B TWI561525 B TW I561525B TW 101144467 A TW101144467 A TW 101144467A TW 101144467 A TW101144467 A TW 101144467A TW I561525 B TWI561525 B TW I561525B
- Authority
- TW
- Taiwan
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011259662 | 2011-11-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201329078A TW201329078A (zh) | 2013-07-16 |
| TWI561525B true TWI561525B (zh) | 2016-12-11 |
Family
ID=48535467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW101144467A TW201329078A (zh) | 2011-11-29 | 2012-11-28 | 嘌呤酮衍生物鹽酸鹽 |
Country Status (30)
| Country | Link |
|---|---|
| US (8) | US9199997B2 (zh) |
| EP (1) | EP2786996B1 (zh) |
| JP (1) | JP5704252B2 (zh) |
| KR (3) | KR101636631B1 (zh) |
| CN (1) | CN103958513B (zh) |
| AU (2) | AU2012344839B2 (zh) |
| BR (2) | BR112014012727B1 (zh) |
| CA (1) | CA2857150C (zh) |
| CY (1) | CY1118376T1 (zh) |
| DK (1) | DK2786996T3 (zh) |
| ES (1) | ES2601219T3 (zh) |
| HK (1) | HK1197819A1 (zh) |
| HR (1) | HRP20161377T1 (zh) |
| HU (1) | HUE031094T2 (zh) |
| IL (1) | IL232822B (zh) |
| LT (1) | LT2786996T (zh) |
| MX (1) | MX353548B (zh) |
| MY (1) | MY170062A (zh) |
| NZ (1) | NZ626750A (zh) |
| PH (1) | PH12014501503A1 (zh) |
| PL (1) | PL2786996T3 (zh) |
| PT (1) | PT2786996T (zh) |
| RS (1) | RS55542B1 (zh) |
| RU (2) | RU2615999C2 (zh) |
| SG (1) | SG11201402658YA (zh) |
| SI (1) | SI2786996T1 (zh) |
| SM (1) | SMT201600426B (zh) |
| TW (1) | TW201329078A (zh) |
| WO (1) | WO2013081016A1 (zh) |
| ZA (1) | ZA201404792B (zh) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7366522B2 (en) | 2000-02-28 | 2008-04-29 | Thomas C Douglass | Method and system for location tracking |
| US7905832B1 (en) | 2002-04-24 | 2011-03-15 | Ipventure, Inc. | Method and system for personalized medical monitoring and notifications therefor |
| US9049571B2 (en) | 2002-04-24 | 2015-06-02 | Ipventure, Inc. | Method and system for enhanced messaging |
| MX2012013622A (es) | 2010-05-31 | 2013-02-01 | Ono Pharmaceutical Co | Derivado de purinona. |
| BR112014012727B1 (pt) | 2011-11-29 | 2022-10-25 | Ono Pharmaceutical Co., Ltd | Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica |
| RU2662805C2 (ru) * | 2013-07-25 | 2018-07-31 | Басф Се | Соли дасатиниба в кристаллической форме |
| US9884857B2 (en) | 2013-07-25 | 2018-02-06 | Basf Se | Salts of dasatinib in amorphous form |
| EP3066126B1 (en) * | 2013-11-07 | 2019-03-27 | F. Hoffmann-La Roche AG | Combination therapy of an anti cd20 antibody with a btk inhibitor |
| US10328080B2 (en) | 2013-12-05 | 2019-06-25 | Acerta Pharma, B.V. | Therapeutic combination of PI3K inhibitor and a BTK inhibitor |
| CN106456642A (zh) | 2014-03-12 | 2017-02-22 | 诺华股份有限公司 | 含btk抑制剂与akt抑制剂的组合 |
| JP6528779B2 (ja) * | 2014-03-25 | 2019-06-12 | 小野薬品工業株式会社 | びまん性大細胞型ｂ細胞リンパ腫の予防および／または治療剤 |
| WO2015185998A2 (en) | 2014-04-11 | 2015-12-10 | Acerta Pharma B.V. | Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase |
| WO2015181633A2 (en) | 2014-04-11 | 2015-12-03 | Acerta Pharma B.V. | Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase |
| TW201618783A (zh) | 2014-08-07 | 2016-06-01 | 艾森塔製藥公司 | 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法 |
| ES2921875T3 (es) | 2014-08-11 | 2022-09-01 | Acerta Pharma Bv | Combinaciones terapéuticas de un inhibidor BTK, un inhibidor PD-1 y/o un inhibidor PD-L1 |
| TW201618773A (zh) | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物 |
| US20170231995A1 (en) | 2014-08-11 | 2017-08-17 | Acerta Pharma B.V. | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment |
| HRP20211813T1 (hr) | 2014-08-11 | 2022-03-04 | Acerta Pharma B.V. | Terapeutske kombinacije inhibitora btk i inhibitora bcl-2 |
| WO2016087994A1 (en) | 2014-12-05 | 2016-06-09 | Acerta Pharma B.V. | Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment |
| MD3097102T2 (ro) | 2015-03-04 | 2018-02-28 | Gilead Sciences Inc | Compuşi de 4,6-diamino-pirido[3,2-D]pirimidină modulatori ai receptorilor de tip Toll |
| US10239879B2 (en) | 2015-04-09 | 2019-03-26 | Ono Pharmaceutical Co., Ltd. | Process for producing purinone derivative |
| HUE055419T2 (hu) * | 2015-06-03 | 2021-11-29 | Principia Biopharma Inc | Tirozinkináz-inhibitorok |
| EP3313405A1 (en) * | 2015-06-23 | 2018-05-02 | Gilead Sciences, Inc. | Combination therapies for treating b-cell malignancies |
| US20190008859A1 (en) | 2015-08-21 | 2019-01-10 | Acerta Pharma B.V. | Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor |
| US20210292327A1 (en) | 2015-08-26 | 2021-09-23 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
| CN105753863B (zh) * | 2015-09-11 | 2018-07-31 | 东莞市真兴贝特医药技术有限公司 | 氧代二氢咪唑并吡啶类化合物及其应用 |
| MA44909A (fr) | 2015-09-15 | 2018-07-25 | Acerta Pharma Bv | Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk |
| WO2017046746A1 (en) | 2015-09-15 | 2017-03-23 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist |
| WO2017059224A2 (en) | 2015-10-01 | 2017-04-06 | Gilead Sciences, Inc. | Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers |
| WO2017059252A1 (en) * | 2015-10-02 | 2017-04-06 | Gilead Sciences, Inc. | Combinations of the btk inhibitor gs-4059 with inhibitors selected from a jak, ask1, brd and/or mmp9 inhibitor to treat cancer, allergic disorders, autoimmune diseases or inflammatory diseases |
| DK3402503T3 (da) * | 2016-01-13 | 2020-12-21 | Acerta Pharma Bv | Terapeutiske kombinationer af et antifolat og en btk-hæmmer |
| CN107021963A (zh) | 2016-01-29 | 2017-08-08 | 北京诺诚健华医药科技有限公司 | 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用 |
| MX2018014377A (es) | 2016-05-27 | 2019-03-14 | Gilead Sciences Inc | Metodos para tratar infecciones por virus de hepatitis b usando inhibidores de proteina no estructural 5a (ns5a), proteina no estructural 5b (ns5b) o proteina no estructural 3 (ns3). |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| PT3507276T (pt) | 2016-09-02 | 2022-01-11 | Gilead Sciences Inc | Compostos moduladores do recetor de tipo toll |
| IL265921B1 (en) | 2016-10-14 | 2024-01-01 | Prec Biosciences Inc | Transgenic meganonucleases specific for recognition sequences in the hepatitis B virus genome |
| MA46995A (fr) | 2016-12-03 | 2019-10-09 | Acerta Pharma Bv | Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase |
| US20190376971A1 (en) | 2017-01-19 | 2019-12-12 | Acerta Pharma B.V. | Compositions and Methods for the Assessment of Drug Target Occupancy for Bruton's Tyrosine Kinase |
| AR110768A1 (es) | 2017-01-31 | 2019-05-02 | Gilead Sciences Inc | Formas cristalinas de tenofovir alafenamida |
| JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
| EP3585789A1 (en) * | 2017-02-24 | 2020-01-01 | Gilead Sciences, Inc. | Inhibitors of bruton's tyrosine kinase |
| CA3054403A1 (en) * | 2017-02-24 | 2018-08-30 | Gilead Sciences, Inc. | Inhibitors of bruton's tyrosine kinase |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| KR20200043439A (ko) | 2017-08-22 | 2020-04-27 | 길리애드 사이언시즈, 인코포레이티드 | 치료 헤테로시클릭 화합물 |
| AU2018392212B9 (en) | 2017-12-20 | 2021-03-18 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| UA126458C2 (uk) | 2018-02-13 | 2022-10-05 | Гіліад Сайєнсіз, Інк. | Інгібітори pd-1/pd-l1 |
| EP3759109B1 (en) | 2018-02-26 | 2023-08-30 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| WO2019193543A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| JP7242702B2 (ja) | 2018-04-19 | 2023-03-20 | ギリアード サイエンシーズ， インコーポレイテッド | Ｐｄ－１／ｐｄ－ｌ１阻害剤 |
| US20210113568A1 (en) | 2018-04-27 | 2021-04-22 | Ono Pharmaceutical Co., Ltd. | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT |
| TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’－環二核苷酸 |
| AU2019297362B2 (en) | 2018-07-06 | 2022-05-26 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| CN112384283B (zh) | 2018-07-06 | 2023-08-15 | 吉利德科学公司 | 治疗性的杂环化合物 |
| TWI732245B (zh) | 2018-07-13 | 2021-07-01 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| CN112424207B (zh) | 2018-07-25 | 2024-03-19 | 诺华股份有限公司 | Nlrp3炎性小体抑制剂 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CA3117556A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| EP3873608A1 (en) | 2018-10-31 | 2021-09-08 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| JP7350872B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | ３’３’－環状ジヌクレオチドおよびそのプロドラッグ |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| CN113543851A (zh) | 2019-03-07 | 2021-10-22 | 捷克共和国有机化学与生物化学研究所 | 2’3’-环二核苷酸及其前药 |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| US20220305115A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| EP3990476A1 (en) | 2019-06-25 | 2022-05-04 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
| US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| CN114555799A (zh) | 2019-09-30 | 2022-05-27 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
| US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| EP4069729A1 (en) | 2019-12-06 | 2022-10-12 | Precision BioSciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| EP4121437A1 (en) | 2020-03-20 | 2023-01-25 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| CN113527300B (zh) * | 2020-06-04 | 2023-02-03 | 广州百霆医药科技有限公司 | 布鲁顿酪氨酸蛋白激酶抑制剂 |
| EP4192474A1 (en) | 2020-08-07 | 2023-06-14 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| WO2022034529A1 (en) | 2020-08-14 | 2022-02-17 | Novartis Ag | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| US20230391752A1 (en) | 2020-10-22 | 2023-12-07 | Chulalongkorn University | Pyrrolidine-3-carboxamide derivatives and related uses |
| WO2022241134A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2023110970A1 (en) | 2021-12-14 | 2023-06-22 | Netherlands Translational Research Center Holding B.V | Macrocyclic btk inhibitors |
| WO2023110936A1 (en) | 2021-12-14 | 2023-06-22 | Netherlands Translational Research Center Holding B.V | Reversible macrocyclic kinase inhibitors |
| US20240067627A1 (en) | 2022-08-03 | 2024-02-29 | Novartis Ag | Nlrp3 inflammasome inhibitors |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008039218A2 (en) * | 2006-09-22 | 2008-04-03 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1077271A (ja) | 1996-09-04 | 1998-03-24 | Toa Eiyoo Kk | ３−ピリジルアミノ化合物またはその塩を含有する循環器官用剤 |
| US7071199B1 (en) | 1999-09-17 | 2006-07-04 | Abbott Gmbh & Cco. Kg | Kinase inhibitors as therapeutic agents |
| DE60037455T2 (de) * | 1999-09-17 | 2008-11-27 | Abbott Gmbh & Co. Kg | Kinaseinhibitoren als arzneimittel |
| CA2465328C (en) | 2001-11-01 | 2011-06-14 | Michael Francis Gross | Piperidines |
| EP1651648A4 (en) | 2003-07-29 | 2009-09-02 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS |
| US7312243B1 (en) | 2003-08-29 | 2007-12-25 | Jay Pravda | Materials and methods for treatment of gastrointestinal disorders |
| LT2439273T (lt) | 2005-05-09 | 2019-05-10 | Ono Pharmaceutical Co., Ltd. | Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais |
| CA2653941C (en) | 2006-05-31 | 2013-01-08 | The Regents Of The University Of California | Substituted amino purine derivatives and uses thereof |
| JP4896673B2 (ja) | 2006-11-09 | 2012-03-14 | Ｎｔｎ株式会社 | 固定式等速自在継手及びその製造方法 |
| BRPI0622030A2 (pt) | 2006-11-16 | 2014-04-22 | Pharmacopeia Llc | Derivados de purina 7-substituída, para imunossupressão |
| EP2560007A1 (en) * | 2007-03-28 | 2013-02-20 | Pharmacyclics, Inc. | Identification of bruton's tyrosine kinase inhibitors |
| EP3311818A3 (en) * | 2008-07-16 | 2018-07-18 | Pharmacyclics, LLC | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
| TWI409079B (zh) | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法 |
| MX2012013622A (es) | 2010-05-31 | 2013-02-01 | Ono Pharmaceutical Co | Derivado de purinona. |
| JP4930625B2 (ja) * | 2010-06-03 | 2012-05-16 | ダイキン工業株式会社 | 油冷却装置 |
| EP2578505B1 (en) * | 2011-10-03 | 2014-07-23 | Tetra Laval Holdings & Finance S.A. | Packaging machine and method for producing sealed packages of a food product from a web of a packaging material |
| KR20230109775A (ko) | 2011-10-19 | 2023-07-20 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 인산화효소(btk)의 억제제의 용도 |
| BR112014012727B1 (pt) | 2011-11-29 | 2022-10-25 | Ono Pharmaceutical Co., Ltd | Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica |
| US20140120083A1 (en) | 2012-11-01 | 2014-05-01 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| TW201427667A (zh) | 2012-11-20 | 2014-07-16 | Celgene Avilomics Res Inc | 治療和布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶相關之疾病或失調的方法 |
| DK3003309T3 (da) | 2013-05-30 | 2020-12-14 | Infinity Pharmaceuticals Inc | Behandling af cancer med PI3-kinase-isoform modulatorer |
| BR112016009200A8 (pt) | 2013-10-25 | 2020-03-24 | Pharmacyclics Llc | uso de um inibidor de btk e um inibidor imune do ponto de verificação |
| EP3066126B1 (en) | 2013-11-07 | 2019-03-27 | F. Hoffmann-La Roche AG | Combination therapy of an anti cd20 antibody with a btk inhibitor |
| US10328080B2 (en) | 2013-12-05 | 2019-06-25 | Acerta Pharma, B.V. | Therapeutic combination of PI3K inhibitor and a BTK inhibitor |
| US10272083B2 (en) | 2014-01-21 | 2019-04-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| ES2921875T3 (es) | 2014-08-11 | 2022-09-01 | Acerta Pharma Bv | Combinaciones terapéuticas de un inhibidor BTK, un inhibidor PD-1 y/o un inhibidor PD-L1 |
| HRP20211813T1 (hr) | 2014-08-11 | 2022-03-04 | Acerta Pharma B.V. | Terapeutske kombinacije inhibitora btk i inhibitora bcl-2 |
-
2012
- 2012-11-28 BR BR112014012727-1A patent/BR112014012727B1/pt active IP Right Grant
- 2012-11-28 MX MX2014006345A patent/MX353548B/es active IP Right Grant
- 2012-11-28 TW TW101144467A patent/TW201329078A/zh unknown
- 2012-11-28 EP EP12852725.6A patent/EP2786996B1/en active Active
- 2012-11-28 CA CA2857150A patent/CA2857150C/en active Active
- 2012-11-28 MY MYPI2014701362A patent/MY170062A/en unknown
- 2012-11-28 PT PT128527256T patent/PT2786996T/pt unknown
- 2012-11-28 HU HUE12852725A patent/HUE031094T2/en unknown
- 2012-11-28 SG SG11201402658YA patent/SG11201402658YA/en unknown
- 2012-11-28 CN CN201280058152.6A patent/CN103958513B/zh active Active
- 2012-11-28 LT LTEP12852725.6T patent/LT2786996T/lt unknown
- 2012-11-28 KR KR1020147014226A patent/KR101636631B1/ko active IP Right Grant
- 2012-11-28 PL PL12852725T patent/PL2786996T3/pl unknown
- 2012-11-28 DK DK12852725.6T patent/DK2786996T3/en active
- 2012-11-28 AU AU2012344839A patent/AU2012344839B2/en active Active
- 2012-11-28 BR BR122022001235-3A patent/BR122022001235B1/pt active IP Right Grant
- 2012-11-28 KR KR1020167005058A patent/KR102021651B1/ko active IP Right Grant
- 2012-11-28 RS RS20160983A patent/RS55542B1/sr unknown
- 2012-11-28 US US14/360,725 patent/US9199997B2/en active Active
- 2012-11-28 RU RU2014126396A patent/RU2615999C2/ru active
- 2012-11-28 ES ES12852725.6T patent/ES2601219T3/es active Active
- 2012-11-28 WO PCT/JP2012/080769 patent/WO2013081016A1/ja active Application Filing
- 2012-11-28 SI SI201230740A patent/SI2786996T1/sl unknown
- 2012-11-28 NZ NZ626750A patent/NZ626750A/en unknown
- 2012-11-28 JP JP2013547190A patent/JP5704252B2/ja active Active
- 2012-11-28 RU RU2017111078A patent/RU2750538C2/ru active
- 2012-11-28 KR KR1020187008777A patent/KR20180034705A/ko not_active Application Discontinuation
-
2014
- 2014-05-27 IL IL232822A patent/IL232822B/en active IP Right Grant
- 2014-06-27 PH PH12014501503A patent/PH12014501503A1/en unknown
- 2014-06-27 ZA ZA2014/04792A patent/ZA201404792B/en unknown
- 2014-11-04 HK HK14111162.3A patent/HK1197819A1/zh unknown
-
2015
- 2015-06-12 US US14/737,595 patent/US9371325B2/en active Active
-
2016
- 2016-05-19 US US15/158,993 patent/US9896453B2/en active Active
- 2016-10-24 HR HRP20161377TT patent/HRP20161377T1/hr unknown
- 2016-11-23 SM SM201600426T patent/SMT201600426B/it unknown
- 2016-11-25 CY CY20161101227T patent/CY1118376T1/el unknown
-
2017
- 2017-02-20 AU AU2017201134A patent/AU2017201134C1/en active Active
- 2017-07-19 US US15/653,614 patent/US9981966B2/en active Active
-
2018
- 2018-04-27 US US15/964,333 patent/US10370377B2/en active Active
-
2019
- 2019-06-25 US US16/451,538 patent/US10807981B2/en active Active
-
2020
- 2020-09-16 US US17/022,529 patent/US11292795B2/en active Active
-
2022
- 2022-02-24 US US17/679,627 patent/US11897885B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008039218A2 (en) * | 2006-09-22 | 2008-04-03 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |